CD30 expression in a case of intravascular large B-cell lymphoma, cutaneous variant

Matteo Provasi, Bagnoli Filippo, Fanoni Daniele, Silvia Alberti Violetti, Tomasini Dario, Emilio Berti

Research output: Contribution to journalArticle

Abstract

Intravascular large B-cell lymphoma (IVLBCL) is one of the rarest B-cell non-Hodgkin lymphomas (NHL), with an aggressive clinical behavior and a poor prognosis; in fact, its treatment is still an unmet clinical need, with a 3-year overall survival (OS) rate of 60% to 81%, and a central nervous system relapse rate of 25%. It usually presents as a widespread disease at diagnosis, with multi-organ involvement. Previously considered as a diffuse large B-cell lymphoma variant, it now represents a different extranodal large B-cell lymphoma entity in the last WHO Classification of tumors of hematopoietic and lymphoid tissues. We hereby describe the case of an 84-year-old Italian woman with an IVLBCL, cutaneous variant, who suffered from early relapse after R-COMP chemotherapy regimen, and was therefore treated with a palliative metronomic chemotherapy. Interestingly, neoplastic cells showed CD30 expression at relapse. CD30 positivity has never been reported in this disease so far, and its expression is known to be involved in NF-kB activation. CD30 expression may be further studied as for prognostic and therapeutic significance; in fact, new therapeutic strategies, such as antibody-drug conjugate targeting CD30, are now available.

Original languageEnglish
Pages (from-to)447-451
JournalJournal of Cutaneous Pathology
Volume46
Issue number6
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

B-Cell Lymphoma
Skin
Recurrence
Drug Therapy
Lymphoma, Large B-Cell, Diffuse
NF-kappa B
Lymphoid Tissue
Drug Delivery Systems
Non-Hodgkin's Lymphoma
Therapeutics
Survival Rate
Central Nervous System
Antibodies
Neoplasms

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Histology
  • Dermatology

Cite this

CD30 expression in a case of intravascular large B-cell lymphoma, cutaneous variant. / Provasi, Matteo; Filippo, Bagnoli; Daniele, Fanoni; Alberti Violetti, Silvia; Dario, Tomasini; Berti, Emilio.

In: Journal of Cutaneous Pathology, Vol. 46, No. 6, 01.01.2019, p. 447-451.

Research output: Contribution to journalArticle

Provasi, Matteo ; Filippo, Bagnoli ; Daniele, Fanoni ; Alberti Violetti, Silvia ; Dario, Tomasini ; Berti, Emilio. / CD30 expression in a case of intravascular large B-cell lymphoma, cutaneous variant. In: Journal of Cutaneous Pathology. 2019 ; Vol. 46, No. 6. pp. 447-451.
@article{dfa580ec6ba44bc58557607e487a8072,
title = "CD30 expression in a case of intravascular large B-cell lymphoma, cutaneous variant",
abstract = "Intravascular large B-cell lymphoma (IVLBCL) is one of the rarest B-cell non-Hodgkin lymphomas (NHL), with an aggressive clinical behavior and a poor prognosis; in fact, its treatment is still an unmet clinical need, with a 3-year overall survival (OS) rate of 60{\%} to 81{\%}, and a central nervous system relapse rate of 25{\%}. It usually presents as a widespread disease at diagnosis, with multi-organ involvement. Previously considered as a diffuse large B-cell lymphoma variant, it now represents a different extranodal large B-cell lymphoma entity in the last WHO Classification of tumors of hematopoietic and lymphoid tissues. We hereby describe the case of an 84-year-old Italian woman with an IVLBCL, cutaneous variant, who suffered from early relapse after R-COMP chemotherapy regimen, and was therefore treated with a palliative metronomic chemotherapy. Interestingly, neoplastic cells showed CD30 expression at relapse. CD30 positivity has never been reported in this disease so far, and its expression is known to be involved in NF-kB activation. CD30 expression may be further studied as for prognostic and therapeutic significance; in fact, new therapeutic strategies, such as antibody-drug conjugate targeting CD30, are now available.",
author = "Matteo Provasi and Bagnoli Filippo and Fanoni Daniele and {Alberti Violetti}, Silvia and Tomasini Dario and Emilio Berti",
year = "2019",
month = "1",
day = "1",
doi = "10.1111/cup.13446",
language = "English",
volume = "46",
pages = "447--451",
journal = "Journal of Cutaneous Pathology",
issn = "0303-6987",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - CD30 expression in a case of intravascular large B-cell lymphoma, cutaneous variant

AU - Provasi, Matteo

AU - Filippo, Bagnoli

AU - Daniele, Fanoni

AU - Alberti Violetti, Silvia

AU - Dario, Tomasini

AU - Berti, Emilio

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Intravascular large B-cell lymphoma (IVLBCL) is one of the rarest B-cell non-Hodgkin lymphomas (NHL), with an aggressive clinical behavior and a poor prognosis; in fact, its treatment is still an unmet clinical need, with a 3-year overall survival (OS) rate of 60% to 81%, and a central nervous system relapse rate of 25%. It usually presents as a widespread disease at diagnosis, with multi-organ involvement. Previously considered as a diffuse large B-cell lymphoma variant, it now represents a different extranodal large B-cell lymphoma entity in the last WHO Classification of tumors of hematopoietic and lymphoid tissues. We hereby describe the case of an 84-year-old Italian woman with an IVLBCL, cutaneous variant, who suffered from early relapse after R-COMP chemotherapy regimen, and was therefore treated with a palliative metronomic chemotherapy. Interestingly, neoplastic cells showed CD30 expression at relapse. CD30 positivity has never been reported in this disease so far, and its expression is known to be involved in NF-kB activation. CD30 expression may be further studied as for prognostic and therapeutic significance; in fact, new therapeutic strategies, such as antibody-drug conjugate targeting CD30, are now available.

AB - Intravascular large B-cell lymphoma (IVLBCL) is one of the rarest B-cell non-Hodgkin lymphomas (NHL), with an aggressive clinical behavior and a poor prognosis; in fact, its treatment is still an unmet clinical need, with a 3-year overall survival (OS) rate of 60% to 81%, and a central nervous system relapse rate of 25%. It usually presents as a widespread disease at diagnosis, with multi-organ involvement. Previously considered as a diffuse large B-cell lymphoma variant, it now represents a different extranodal large B-cell lymphoma entity in the last WHO Classification of tumors of hematopoietic and lymphoid tissues. We hereby describe the case of an 84-year-old Italian woman with an IVLBCL, cutaneous variant, who suffered from early relapse after R-COMP chemotherapy regimen, and was therefore treated with a palliative metronomic chemotherapy. Interestingly, neoplastic cells showed CD30 expression at relapse. CD30 positivity has never been reported in this disease so far, and its expression is known to be involved in NF-kB activation. CD30 expression may be further studied as for prognostic and therapeutic significance; in fact, new therapeutic strategies, such as antibody-drug conjugate targeting CD30, are now available.

UR - http://www.scopus.com/inward/record.url?scp=85063892093&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063892093&partnerID=8YFLogxK

U2 - 10.1111/cup.13446

DO - 10.1111/cup.13446

M3 - Article

AN - SCOPUS:85063892093

VL - 46

SP - 447

EP - 451

JO - Journal of Cutaneous Pathology

JF - Journal of Cutaneous Pathology

SN - 0303-6987

IS - 6

ER -